SCHEMBL215825

SCHEMBL215825

Cc1ccc(NC(=O)c2[nH]cnc2C(=O)Nc2cc(Br)ccc2C)cc1C

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
KMT2A Q03164 8/20 0.56
ALDH1A1 P00352 7/20 0.56
MEN1 O00255 6/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
KDM4E B2RXH2 5/20 0.56
GAA P10253 3/20 0.52
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
MAPK1 P28482 2/20 0.47
HSD17B10 Q99714 2/20 0.47
HTT P42858 1/20 0.47
HPGD P15428 2/20 0.46
CYP1A2 P05177 1/20 0.46
TP53 P04637 1/20 0.46
LMNA P02545 1/20 0.46
MAPK10 P53779 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213976 0.91 MAPT (0.71) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL214575 0.89 MAPT (0.53) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL214246 0.89 MAPT (0.53) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL215229 0.89 MAPT (0.63) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL215861 0.89 KMT2A (0.63) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL14222951 0.89 MAPT (0.67) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL213701 0.88 MAPT (0.75) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL214746 0.87 MAPT (0.74) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL215331 0.86 ALDH1A1 (0.61) MAPTKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL14222316 0.85 GAA (0.54) MAPTKMT2AALDH1A1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 MAPT 2138/4885KMT2A 437/4885ALDH1A1 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.